About Lymphoma | Advocacy | Art | CAM | Clinical trials | Doctors - Experts - Centers | Guidelines at Diagnosis | News
Risk Factors | Side Effects | Statistics | Support | Symptoms | Tests | Treatments | Types of Lymphoma

Search Site         Guidelines at Diagnosis | About Clinical Trials            How to Help!

Patients Against Lymphoma


Treatment Overview > Review Article

Last update: 11/27/2011

Syngeneic Hematopoietic Stem-Cell Transplantation for Non-Hodgkin's Lymphoma: A Comparison With Allogeneic and Autologous Transplantation

(Syngeneic. The donor is an identical twin of the patient.)

--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.

Bierman PJ, Sweetenham JW, Loberiza Jr FR, Taghipour G, Lazarus HM, 
Rizzo JD, Schmitz N, Besien Kv K, Vose JM, Horowitz M, Goldstone A.

University of Nebraska Medical Center, Omaha, NE; University of Colorado Health Sciences Center, Denver, CO; International Bone Marrow Transplant Registry, Milwaukee, WI; University College 
Hospital, London, United Kingdom; Ireland Cancer Center, Cleveland, OH; Christian Albrechts University, Kiel, Germany; and University of Chicago, Chicago, IL.

PURPOSE: To compare results of syngeneic, allogeneic, and autologous hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma (NHL). 


The databases of the International Bone Marrow Transplant Registry (IBMTR) and the European Group for Blood and Marrow Transplantation were used to-identify 89 NHL patients who received syngeneic transplants 

These patients were compared with NHL patients identified from the IBMTR and the Autologous Blood and Marrow Transplant Registry who received allogeneic (T-cell depleted and T-cell replete) and autologous (purged and unpurged) transplants. 


No significant differences in relapse rates were observed when results of allogeneic transplantation were compared with syngeneic transplantation for any histology. 

T-cell depletion of allografts was not associated with a higher relapse risk, but was associated with improved overall survival for patients with low-grade and intermediate-grade histology. 

Patients who received unpurged autografts for low-grade NHL had a five-fold (P > =.008) greater risk of relapse than recipients of syngeneic transplants, and recipients of unpurged autografts had a two-fold (P=.0009) greater relapse risk than patients who received purged autografts. 

Among low-grade NHL patients, the use of purging was associated with significantly better disease-free survival (P =.003) and overall survival (P =.04) when compared with patients who received unpurged autografts. 

These analyses failed to find evidence of a graft-versus-lymphoma effect, but do provide indirect evidence to support the hypothesis that tumor contamination may contribute to lymphoma relapse, and that purging may be beneficial for patients undergoing autologous hematopoietic stem-cell transplantation for low-grade NHL.

PMID: 12963703 


Disclaimer:  The information on Lymphomation.org is not intended to be a substitute for 
professional medical advice or to replace your relationship with a physician.
For all medical concerns,  you should always consult your doctor. 
Patients Against Lymphoma, Copyright 2004,  All Rights Reserved.